(Q34699979)

English

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients (English)

1 reference

Europe PubMed Central

4 August 2017

0 references

amyotrophic lateral sclerosis

0 references

0 references

1 reference

based on heuristic

inferred from title

3

object named as

Gen Sobue

1 reference

Europe PubMed Central

4 August 2017

author name string

Koji Abe

1

1 reference

Europe PubMed Central

4 August 2017

Yasuto Itoyama

2

1 reference

Europe PubMed Central

4 August 2017

Shoji Tsuji

4

1 reference

Europe PubMed Central

4 August 2017

Masashi Aoki

5

1 reference

Europe PubMed Central

4 August 2017

Manabu Doyu

6

1 reference

Europe PubMed Central

4 August 2017

Chikuma Hamada

7

1 reference

Europe PubMed Central

4 August 2017

Kazuoki Kondo

8

1 reference

Europe PubMed Central

4 August 2017

Takatomo Yoneoka

9

1 reference

Europe PubMed Central

4 August 2017

Makoto Akimoto

10

1 reference

Europe PubMed Central

4 August 2017

Hiide Yoshino

11

1 reference

Europe PubMed Central

4 August 2017

Edaravone ALS Study Group

12

1 reference

Europe PubMed Central

4 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 October 2014

1 reference

Europe PubMed Central

4 August 2017

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

1 reference

Europe PubMed Central

4 August 2017

15

1 reference

Europe PubMed Central

4 August 2017

7-8

1 reference

Europe PubMed Central

4 August 2017

610-617

1 reference

Europe PubMed Central

4 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

6 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Prognostic factors in ALS: A critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Amyotrophic lateral sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Defining optimal management in ALS: from first symptoms to announcement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

7 July 2018

Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia.

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

26 October 2018

Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

26 October 2018

Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4266079

26 October 2018

Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

ALS, SOD and peroxynitrite

1 reference

https://api.crossref.org/works/10.3109%2F21678421.2014.959024

21 January 2018

Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger

1 reference

https://pubmed.ncbi.nlm.nih.gov/25286015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis--assessment questionnaire 40 (ALSAQ-40)]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25286015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25286015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25286015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25286015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25286015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25286015

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/21678421.2014.959024

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34699979&oldid=1797874026"